ClearPoint Neuro, Inc. (CLPT) stock
Close on Nov 11, 2026Market cap $293.94MP/E –Yield –
ClearPoint Neuro, Inc. grew revenue 32.5% to $45.49M over the twelve months to Sep 30, 2026. Free cash flow was -$48.18M. At the latest close the market valued the company at $293.94M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $293.94M
- P/E ratio
- –
- Price to sales
- 6.46
- Price to book
- 10.78
- Dividend yield
- –
- Free cash flow yield
- -16.39%
Fundamentals
- Revenue
- $45.49M
- Net income
- -$36.14M
- EPS, diluted
- -$1.21
- Free cash flow
- -$48.18M
- Book value per share
- $0.88
- Diluted shares
- 31M
Trading
- Next earnings
- Mar 16, 2027 (estimated, after the close)
- Previous close
- $8.77
- Open
- $8.98
- Day's range
- $8.81 – $9.24
- Volume
- 440,262
- Average volume (20 days)
- 697,872
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Aug 2025)
- Beta (5 years)
- 1.83
- 52-week range
- $8.27 – $19.63
- RSI (14 days)
- 42.2
- Volatility (1 year)
- 85.5%
- Relative volume
- 0.68×
- WACC
- 13.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLPT | S&P 500 | Difference | CLPT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.5% | -2.4% | −10.1 pts | ||
| 3 months | -38.5% | -1.2% | −37.3 pts | ||
| Year to date | -33.0% | +12.3% | −45.3 pts | ||
| 1 year | -47.3% | +12.4% | −59.7 pts | ||
| 3 years | +105.6% | +78.8% | +26.8 pts | +27.2% | +21.4% |
| 5 years | -44.5% | +75.2% | −119.6 pts | -11.1% | +11.9% |
| 10 years | +129.3% | +311.1% | −181.9 pts | +8.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ClearPoint Neuro filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About ClearPoint Neuro
Surgical & Medical Instruments & Apparatus
ClearPoint Neuro is a medical device company that develops and commercializes systems for minimally invasive brain surgeries and neurocritical care. The company operates two main segments: neurosurgical medical devices and biologics and drug delivery partnerships. Its core device products include the ClearPoint navigation platform with associated hardware, disposable instruments, and software, as well as the ClearPoint Prism laser therapy system and the IRRAflow fluid exchange system. In biologics and drug delivery, it provides preclinical consulting, study design, and testing services. Its clients comprise acute care hospitals, neurosurgeons, academic institutions, contract research organizations, and pharmaceutical and biotechnology companies.
Company profile, executives and historyClearPoint Neuro stock: common questions
What is ClearPoint Neuro's stock price?
CLPT closed at $9.17 on Nov 11, 2026, up 4.56% on the day. Over the past 52 weeks it traded between $8.27 and $19.63.
What is ClearPoint Neuro's market cap?
ClearPoint Neuro was worth $293.94M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CLPT's P/E ratio?
ClearPoint Neuro lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
How much revenue does ClearPoint Neuro make?
ClearPoint Neuro reported revenue of $45.49M for the twelve months to Sep 30, 2026, up 32.5% from a year earlier.
Does ClearPoint Neuro pay a dividend?
No. ClearPoint Neuro has not paid a cash dividend over the last twelve months.
When does ClearPoint Neuro report earnings next?
ClearPoint Neuro is expected to report Q4 FY2026 results on Mar 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CLPT stock performed over the past year?
Including dividends, CLPT returned -47.3% over the past year, against +12.4% for the S&P 500.
How many CLPT shares are sold short?
4M shares were sold short at the latest FINRA report, 13.90% of the float, or 6.6 days of average trading volume.
Who are ClearPoint Neuro's competitors?
Companies most similar to ClearPoint Neuro by business, industry and size include BWAY, KRMD, LNSR, CVRX, OBIO.
See a number that looks wrong?